Outlook Therapeutics Inc.

OTLK | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.68

-$0.01 (-0.92%)

Sep 22, 2026, 9:42 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.92%

(1D)

Rating

Updated: Sep 1, 2026

42.5

Fundamentals Average

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $127.53M

1D Range

0.68 0.69

52W Range

0.16 2.54

Valuation (TTM)

PE -0.57

PB 4.90

EV/EBITDA -1.88

Valuation (NTM)

Forward PE N/A

Forward PEG 0.01

Price Target $2.80

Cash Flow

FCF Yield -36.7%

SBC Adj. FCF Yield -40.7%

SBC Impact -10.9%

Margins

Gross Margin 195.6%

Operating Margin 4783.1%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -340.6% | -63.5%

Dil EPS 3Y | 5Y 110.1% | 30.0%

FCF 3Y | 5Y 9.9% | -0.1%

Returns

ROA -233.4%

ROE 222.0%

ROIC -343.7%

Financial Health

Net Cash

$11.24M

Current Ratio 0.81

Interest Coverage -210.62

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye con...

Sector Healthcare

Industry Biotechnology

Employees 17

IPO Date Jun 13, 2016

Website www.outlooktherapeutics.com

Fiscal Year October - September

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Dec 18, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$2.80

Upside

+311.76%

Buy (2)

Hold (2)

Sell (0)

Analyst Details ➞